Many thanks for all who attended our December 1 webinar on “Cannabis and International Trade Issues 2022.” The event was hosted by the National Customs Broker and Freight Forwarders Association of America Educational Institute (NEI).
We received many questions from the audience that we were not able to get to. We plan to cover some of those question here on the blog. Today, I’ll cover considerations around “drug paraphernalia” after the Eteros decision.
Does the panel have any thoughts on the recent Eteros and Keirton decisions at the CIT and the impact of these decisions on the import of drug paraphernalia nationally?
Several attendees raised questions on how treatment by Customs and Border Protection (CBP) of imported products deemed to be inadmissible “drug paraphernalia” would change in light of two recent decisions issued by the Court of International Trade (CIT). The CIT’s decisions (Eteros and Keirton) are significant not just because these decisions are the first time a federal court has rejected CBP’s ruling that certain products were drug paraphernalia, but also because the legal basis for the court’s rejection of CBP offers a clear path for other products to not be deemed drug paraphernalia.
The Controlled Substances Act specifically makes it unlawful
Read full article on HarrisBricken
